Yuansheng Capital is the famous VC, which was founded in 2015.
The top activity for fund was in 2016. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 1 partaker. Despite the Yuansheng Capital, startups are often financed by Tencent Industry Win-Win Fund, CrestValue.
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Roseonly. Among the most popular fund investment industries, there are Internet, Online Forums.
Related Funds
Fund Name | Location |
AD Gilhart & Co | New York, New York, United States |
Allscripts | Chicago, Illinois, United States |
Ameritas Life Insurance | Lincoln, Nebraska, United States |
Bain Capital Double Impact Fund | Boston, Massachusetts, United States |
Chihousousei | Japan, Tokyo |
East West Ventures | California, Los Angeles, United States |
EV Growth | Central, Central Region, Singapore |
FG Angels | Boulder, Colorado, United States |
Honeywell Capital Management | Morristown, New Jersey, United States |
Ivy Capital | China, Shanghai |
Iwashin RITA Partners | - |
LionTree Partners | New York, New York, United States |
Private Advisor Group | - |
S4C Digital Media | Carmarthen, Carmarthenshire, United Kingdom |
Sabre Ventures | - |
Security Dynamics Technologies | Bedford, Massachusetts, United States |
SIPA Ouest France group | - |
Turntide Technologies | - |
Zhongjin Wenhua Xiaofei Jijin | China, Fujian, Xiamen |
Zhongwu Qilian | Beijing, China, Fengtai |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Chromai | $15M | 05 Jun 2023 | Shunyi, Beijing, China | ||
Qcraft | 02 Dec 2022 | Dongcheng District, Beijing, China | |||
ZVISION Technologies | 16 Nov 2022 | Dongcheng District, Beijing, China | |||
Degron Therapeutics | $22M | 09 Jun 2022 | Shanghai, Shanghai, China | ||
Yingsheng Biology | 29 Mar 2022 | Lixia District, Shandong, China | |||
Changmugu Medical | $83M | 10 Nov 2021 | Dongcheng District, Beijing, China | ||
Xiaopangxiong | $400M | 07 Jun 2021 | Shanghai, China | ||
Zhongxuegao | $30M | 18 May 2021 | Shanghai, China | ||
Health Biotech | $30M | 11 May 2021 | Changping, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Chromai | $15M | 05 Jun 2023 | Shunyi, Beijing, China | ||
Qcraft | 02 Dec 2022 | Dongcheng District, Beijing, China | |||
ZVISION Technologies | 16 Nov 2022 | Dongcheng District, Beijing, China | |||
Degron Therapeutics | $22M | 09 Jun 2022 | Shanghai, Shanghai, China | ||
Yingsheng Biology | 29 Mar 2022 | Lixia District, Shandong, China | |||
Changmugu Medical | $83M | 10 Nov 2021 | Dongcheng District, Beijing, China | ||
Xiaopangxiong | $400M | 07 Jun 2021 | Shanghai, China | ||
Zhongxuegao | $30M | 18 May 2021 | Shanghai, China | ||
Health Biotech | $30M | 11 May 2021 | Changping, Beijing, China |